Incyte Corporation  

(Public, NASDAQ:INCY)   Watch this stock  
Find more results for INCY
131.21
+9.26 (7.59%)
Feb 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 127.56 - 131.89
52 week 60.30 - 131.89
Open 128.27
Vol / Avg. 9.23M/1.39M
Mkt cap 26.74B
P/E 243.67
Div/yield     -
EPS 0.54
Shares 189.41M
Beta 0.78
Inst. own 96%
Feb 9, 2017
Q4 2016 Incyte Corp Earnings Release (Estimated)
Jan 9, 2017
Incyte Corp at JPMorgan Healthcare Conference-Q&A Session
Jan 9, 2017
Incyte Corp at JPMorgan Healthcare Conference
Dec 21, 2016
Merus NV and Incyte Corp Global Strategic Research Collaboration - Conference Call - Webcast
Nov 29, 2016
Incyte Corp at Piper Jaffray Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin 2.72% 9.43%
Operating margin 12.89% 13.11%
EBITD margin - 18.40%
Return on average assets 2.24% 7.88%
Return on average equity 9.02% 35.29%
Employees 980 -
CDP Score - -

Address

1801 Augustine Cut off
WILMINGTON, DE 19803-4404
United States - Map
+1-302-4986700 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Incyte Corporation is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat medical needs, primarily in oncology. The Company focuses on the research and development program to explore the inhibition of enzymes called janus associated kinases (JAK). The Company's pipeline includes compounds in various stages, ranging from preclinical to late stage development, and a commercialized product, JAKAFI (ruxolitinib). The Company has discovered multiple potent, selective and orally bioavailable JAK inhibitors that are selective for JAK1 or JAK1 and JAK2. JAKAFI is the compound in its JAK program, which is an oral JAK1 and JAK2 inhibitor. JAKAFI orphan drug is indicated for Myelofibrosis (MF), Polycythemia Vera (PV) and essential thrombocythemia. The Company's second oral JAK1 and JAK2 inhibitor is baricitinib.

Officers and directors

Herve Hoppenot Chairman of the Board, President, Chief Executive Officer
Age: 56
Bio & Compensation  - Reuters
David W. Gryska Chief Financial Officer, Executive Vice President
Age: 60
Bio & Compensation  - Reuters
Reid M. Huber Executive Vice President, Chief Scientific Officer
Age: 44
Bio & Compensation  - Reuters
Eric H. Siegel Executive Vice President, General Counsel
Age: 51
Bio & Compensation  - Reuters
Paula J. Swain Executive Vice President - Human Resources
Age: 58
Bio & Compensation  - Reuters
Barry P. Flannelly Executive Vice President and General Manager , US
Age: 58
Bio & Compensation  - Reuters
Wenqing Yao Ph.D. Executive Vice President - Discovery Medicinal and Process Chemistry
Age: 53
Bio & Compensation  - Reuters
Julian C. Baker Lead Independent Director
Age: 50
Bio & Compensation  - Reuters
Paul A. Friedman M.D. Director
Age: 73
Bio & Compensation  - Reuters
Jean-Jacques Bienaime Independent Director
Age: 62
Bio & Compensation  - Reuters